z-logo
open-access-imgOpen Access
Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy
Author(s) -
Rob GlynneJones,
Neel Bhuva,
Mark Harrison
Publication year - 2020
Publication title -
colorectal cancer
Language(s) - English
Resource type - Journals
eISSN - 1758-1958
pISSN - 1758-194X
DOI - 10.2217/crc-2019-0010
Subject(s) - medicine , chemoradiotherapy , quality of life (healthcare) , colorectal cancer , sexual function , radiation therapy , population , colostomy , oncology , stage (stratigraphy) , anal cancer , surgery , intensive care medicine , cancer , nursing , paleontology , environmental health , biology
The aim was to examine the current trend in rectal cancer, which is to extend ’watch-and-wait’ to earlier-stage tumors, not normally treated with chemoradiotherapy, to define the up-side and down-side regarding quality of life (QOL) and anorectal/sexual/urinary function from this approach. We reviewed the literature regarding a ‘watch-and-wait’ strategy after neoadjuvant chemoradiotherapy. The primary outcome measure was complete clinical response. Secondary measures included colostomy rate, functional outcomes and QOL. There is a trend to use chemoradiotherapy in earlier tumors using dose-escalation of radiation and/or additional chemotherapy, resulting in high rates of complete clinical response, which may impact adversely on QOL if radical surgery is subsequently required. Focusing on organ-preservation as the primary goal of treatment rather than overall functional outcomes and QOL for the whole population, may not provide patients with sufficient information for optimal decision-making.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom